Table 2. The relationship between positivity of anti-NY-ESO-1 antibodies and pathological characteristics.
| Characteristic | Anti-NY-ESO-1 (+) (n = 19) |
Anti-NY-ESO-1 (–) (n = 84) |
P |
|---|---|---|---|
| Differentiation (n, %) | |||
| Well differentiation | 4 (21.1) | 44 (52.4) | 0.01 |
| Poorly differentiation | 15 (78.9) | 40 (47.6) | |
| Tumor size (n, %) | |||
| ≤5 cm | 6 (31.6) | 32 (38.1) | 0.60 |
| >5 cm | 13 (68.4) | 52 (61.9) | |
| Portal invasion | |||
| Yes | 12 (63.2) | 33 (39.3) | 0.06 |
| No | 7 (36.8) | 51 (60.7) | |
| Lymphatic metastasis (n, %) | |||
| Yes | 11 (57.9) | 27 (32.1) | 0.04 |
| No | 8 (42.1) | 57 (67.9) | |
| Liver cirrhosis | |||
| Yes | 9 (47.4) | 39 (46.4) | 0.82 |
| No | 10 (52.6) | 45 (43.6) | |
| cTNM stage (n, %) | |||
| I + II | 6 (31.6) | 50 (59.5) | 0.03 |
| III + IV | 13 (68.4) | 34 (40.5) |